Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ekir.2019.07.009
Title: Pilot Study of Renal Urinary Biomarkers for Diagnosis of CKD of Uncertain Etiology
Authors: Fernando, B.N.T.W.
Alli-Shaik, A.
Hemage, R.K.D.
Badurdeen, Z.
Hettiarachchi, T.W.
Abeysundara, H.T.K.
Abeysekara, T.D.J.
Wazil, A.
Rathnayake, S.
Gunaratne, J. 
Nanayakkara, N.
Keywords: chronic kidney disease of uncertain etiology
early diagnosis
urinary biomarkers
Issue Date: 2019
Publisher: Elsevier Inc
Citation: Fernando, B.N.T.W., Alli-Shaik, A., Hemage, R.K.D., Badurdeen, Z., Hettiarachchi, T.W., Abeysundara, H.T.K., Abeysekara, T.D.J., Wazil, A., Rathnayake, S., Gunaratne, J., Nanayakkara, N. (2019). Pilot Study of Renal Urinary Biomarkers for Diagnosis of CKD of Uncertain Etiology. Kidney International Reports 4 (10) : 1401-1411. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ekir.2019.07.009
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International
Abstract: Introduction: Chronic kidney disease of uncertain etiology (CKDu), an emerging chronic kidney disease (CKD) subtype, contributes to significant morbidity and mortality in certain tropical countries. Although several indicators of CKDu have been previously suggested, sensitive and specific tests to detect early disease or predict disease progression are currently unavailable. This study focused on evaluating 8 renal urinary markers, namely neutrophil gelatinase-associated lipocalin (NGAL), Kidney Injury Molecule-1 (KIM1), cystatin C (CST3), beta 2 microglobulin (B2M), osteopontin (OPN), alpha 1 microglobulin (A1M), tissue inhibitor of metalloproteinase 1 (TIMP1), and retinol binding protein 4 (RBP4), with the hypothesis that these have distinct expression patterns in patients with CKDu. Methods: A cross-sectional study was conducted with 5 study groups comprising subjects from CKDu, endemic CKD, nonendemic CKD, and endemic healthy and nonendemic healthy controls. The urinary levels of the 8 selected renal biomarkers were quantified using multiplex biomarker assay, and the data were subjected to systematic analysis using logistic regression algorithm aiming to extract the best marker combination that could distinctly identify the disease groups noninvasively from the healthy controls. Results: A 3-marker signature panel comprising A1M, KIM1, and RBP4 was identified to represent the best minimum marker combination for differentiating all CKD categories, including CKDu, from healthy controls with an overall sensitivity of ?0.867 and specificity ?0.765. The marker combination comprising OPN, KIM1, and RBP4 showed high predictive performance for distinguishing patients with CKDu from patients with CKD with both sensitivity and specificity ?0.93, which was superior to any existing noninvasive indicator. Conclusion: In all, our systematic evaluation of urinary markers previously linked to CKD, in general, allowed identification of exclusive marker panel combination for early diagnosis and confirmation of CKDu. © 2019 International Society of Nephrology
Source Title: Kidney International Reports
URI: https://scholarbank.nus.edu.sg/handle/10635/212434
ISSN: 2468-0249
DOI: 10.1016/j.ekir.2019.07.009
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1016_j_ekir_2019_07_009.pdf944.81 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons